The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus
Open accessAbstract
BACKGROUND: Insulin is widely used to improve metabolic control in patients with non-insulin-dependent diabetes mellitus (NIDDM), but there is no consensus about the optimal regimen of insulin treatment. METHODS: We treated 153 patients with NIDDM for three months with five regimens: (1) oral hypoglycemic drug therapy plus NPH insulin given at 7 a.m. (the morning-NPH group), (2) oral hypoglycemic drug therapy plus NPH insulin given at 9 p.m. (the evening-NPH group), (3) NPH and regular insulin (ratio, 70 units to 30 units) given before breakfast and dinner (the two-insulin-injection group), (4) NPH insulin at 9 p.m. and regular insulin before meals (the multiple-insulin-injection group), and (5) continued oral hypoglycemic drug therapy (the control group). RESULTS: The mean (+/- SE) value for glycosylated hemoglobin decreased similarly in all four insulin-treatment groups (1.7 +/- 0.3, 1.9 +/- 0.2, 1.8 +/- 0.3, and 1.6 +/- 0.3 percent, respectively). The decrease was significantly greater in these four groups than in the control group (0.5 +/- 0.2 percent; P < 0.001 vs. all insulin-treated groups). Weight gain was significantly less (1.2 +/- 0.5 kg) in the evening-NPH group than in the other insulin-treatment groups (2.2 +/- 0.5 kg in the morning-NPH group, 1.8 +/- 0.5 kg in the two-insulin-injection group, and 2.9 +/- 0.5 kg in the multiple-injection group; P < 0.05). In addition, the increment in the mean diurnal serum free insulin concentration was 50 to 65 percent smaller in the evening-NPH group than in the other insulin-treatment groups. Subjective well-being improved significantly more in the insulin-treatment groups than in the control group (P < 0.001). CONCLUSIONS: In patients with NIDDM who are receiving oral hypoglycemic drug therapy, the addition of NPH insulin in the evening improves glycemic control in a manner similar to combination therapy with NPH insulin in the morning, a two-insulin-injection regimen, or a multiple-insulin-injection regimen, but induces less weight gain and hyperinsulinemia. The data thus suggest that patients with NIDDM do not benefit from multiple insulin injections and that nocturnal insulin administration appears preferable to daytime administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Newer “ultra-long-acting” basal insulin analogues, insulin glargine U300, and insulin degludec have been shown to be associated with less hypoglycemia than insulin glargine U100.1072,1073”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1072]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BMDP Statistical Software 1981.
Bubolz, T. A., & Dixon, W. J. (1984) · Journal of the American Statistical Association · doi:10.2307/2288308 · Cited by 5,231
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics
Kuzuya, H., BLIX, P. M., Horwitz, D. L., Steiner, D. F., & Rubenstein, A. H. (1977) · Diabetes · doi:10.2337/diab.26.1.22 · Cited by 603
DIABETES INCIDENCE IN PIMA INDIANS: CONTRIBUTIONS OF OBESITY AND PARENTAL DIABETES1
KNOWLER, W. C., PETTITT, D. J., SAVAGE, P. J., & BENNETT, P. H. (1981) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113079 · Cited by 561
Oates, J. A., Wood, A. J. J., & Gerich, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211805 · Cited by 477
Firth, R. G., Bell, P. M., Marsh, H. W., Hansen, I., & Rizza, R. A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112467 · Cited by 284
Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations
Berger, M., Cüppers, H. J., Hegner, H., Jörgens, V., & Berchtold, P. (1982) · Diabetes Care · doi:10.2337/diacare.5.2.77 · Cited by 249
Andrews, W. J., Vasquez, B., NAGULESPARAN, M., Klimeś, I., Foley, J. E., Unger, R. H., & Reaven, G. M. (1984) · Diabetes · doi:10.2337/diab.33.7.634 · Cited by 194
Taskinen, M., Kuusi, T., Helve, E., Nikkilä, E. A., & Yki‐Järvinen, H. (1988) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.8.2.168 · Cited by 184
Self-citationDetermination of free and total insulin and C-peptide in insulin-treated diabetics
Kuzuya, H., BLIX, P. M., Horwitz, D. L., et al. (1977) · Diabetes · doi:10.2337/diabetes.26.1.22 · Cited by 170
Research works printed but not linked: 2
- Dixon WJ, ed. BMDP statistical software. Berkeley: University of California Press, 1983.
- Hamilton, 1990, Am J Kidney Dis, 16, 20
Cited by
Sorted by citations
Items 201–300 of 322
Chazan, A. C. S., & Gomes, M. B. (2001) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2001000100006 · Cited by 8
Raskin, P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272010 · Cited by 8
Review: Combination treatment with insulin and oral agents in type 2 diabetes mellitus
Burke, J. (2004) · The British Journal of Diabetes · doi:10.1177/14746514040040020201 · Cited by 7
Rodier, M., Colette, C., Gouzes, C., Michel, F., de Paulet, A. C., & Monnier, L. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)96798-8 · Cited by 7
The changing model of insulin use in type 2 diabetes
Cooppan, R. M. (2003) · Postgraduate Medicine · doi:10.3810/pgm.2003.06.1433 · Cited by 7
Clinical Pharmacology of Sulfonylureas
Groop, L., & Neugebauer, G. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-09127-2_9 · Cited by 7
Should Obese Type 2 Diabetic Patients be Treated with Insulin?
Riddle, M. C. (2001) · doi:10.1002/9780470757109.ch7 · Cited by 7
Bergenstal, R. M. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0616 · Cited by 7
Insulin therapy: Side effects and their management
Kashi, Z., Akha, O., Borzouei, S., & Bahar, A. (2013) · Clinical Excellence · Cited by 6
Furlong, N. J., McNulty, S., O'Brien, S., & Hardy, K. (2002) · Practical Diabetes · doi:10.1002/pdi.399 · Cited by 6
Use of Acarbose or Bedtime Insulin after Failure of Treatment with Conventional Oral Antidiabetics
Ko, G. T. C., Tsang, C.-C., Ng, C.-W., Wai, H. P. S., & Kan, E. C. Y. (2001) · Clinical Drug Investigation · doi:10.2165/00044011-200121060-00002 · Cited by 5
Pj, E., IDRIS, I. R., Daly, H., & Scott, A. (2003) · Practical Diabetes · doi:10.1002/pdi.515 · Cited by 5
Factors that influence basal insulin requirement in type 2 diabetes
Papa, G., Baratta, R., Calì, V., Degano, C., Iurato, M. P., Licciardello, C., Maiorana, R., & Finocchiaro, C. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0372-7 · Cited by 5
Al-Shaikh, A. R. (2006) · Cited by 5
New Concepts for Treatment of Non-Insulin-Dependent Diabetes Mellitus
Larkins, R. G. (1997) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(97)00037-4 · Cited by 5
Diabetes Mellitus in Older Patients
Lunt, H. (1996) · Drugs & Aging · doi:10.2165/00002512-199608060-00001 · Cited by 5
Goday, A., Franch‐Nadal, J., Goday, A., Mata, M., Guisasola, F. Á., Espino, J. D., Fernández, I. F., Graner, D. T., Delgado, D. A., Aguilar‐Diosdado, M., et al. (2001) · Atención Primaria · doi:10.1016/s0212-6567(01)79381-x · Cited by 5
Monnier, L., & Halimi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30031-1 · Cited by 4
Actualización en el manejo de los antidiabéticos orales en Aten- ción Primaria
Gomero, L. (2008) · Cited by 4
The Transition from Oral Agents to Combination Insulin/Oral Therapy
Riddle, M. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_11 · Cited by 4
“Studies document the ability of various insulins to supplement endogenous basal insulin levels, including bovine or human ultralente (33), human NPH ( 34 ,35), and human 70/30 (70% NPH/30% Regular) (36), and the insulin analogue glargine (37–39).”
BackgroundManagement of Diabetes Mellitus
Culy, C. R., & Jarvis, B. (2001) · Disease Management & Health Outcomes · doi:10.2165/00115677-200109120-00005 · Cited by 4
“[64,70]”
Therapeutic traditions in type 2 diabetes ? are they changing?
NISKANEN, L. K., Enlund, H., Jormanainen, V. J., Nissinen, A. M., & Uusitupa, M. I. J. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00199870 · Cited by 4
Self-citationEffects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes.
Sinagra, D., Scarpitta, A. M., & Amato, M. P. (1998) · PubMed · Cited by 4
Fritsche, A., Stümvoll, M., & H�ring, H.-U. (2003) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-003-1259-8 · Cited by 4
Comparative Assessment of the Treatment of Type 2 Diabetes Mellitus
Kokić, S., Radman, M., Čapkun, V., Dovžak-Kokić, D., & Tešanović, S. (2002) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2002.163 · Cited by 4
Sinclair, A. J. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0812 · Cited by 4
Outcome of insulin treatment in type 2 diabetic patients with secondary oral hypoglycaemic failure
Akber, M., Clegg, C., Connor, S., & Casson, I. F. (2001) · Practical Diabetes · doi:10.1002/pdi.124 · Cited by 4
Objetivos y estrategia terapéutica en la diabetes mellitus tipo 2
Romero, J. M. C., & Rodríguez, E. M. L. (2001) · Anales de Medicina Interna · doi:10.4321/s0212-71992001000700010 · Cited by 4
Comparison of Acute Daytime and Nocturnal Insulinization on Diurnal Glucose Homeostasis in NIDDM
Puhakainen, I., Taskinen, M., & Yki‐Järvinen, H. (1994) · Diabetes Care · doi:10.2337/diacare.17.8.805 · Cited by 4
“In our multicenter study comparing combination therapy regimens with either evening insulin or morning insulin, we found comparable improvements in glycemic control using both regimens (4).”
BackgroundResultInfluentialSelf-citationNew concepts in diabetes mellitus. I: Treatment, pregnancy and aetiology
Taylor, R., & Vanderpump, M. P. J. (1994) · Postgraduate Medical Journal · doi:10.1136/pgmj.70.824.418 · Cited by 3
Echtay, A. S., Andari, E., Atallah, P., Moufarrege, R., & Nemr, R. (2017) · Ethnicity & Disease · doi:10.18865/ed.27.1.45 · Cited by 3
Insulin and New Insulin Analogues with Focus on Type 2 Diabetes
Madsbad, S. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_7 · Cited by 3
“Adding basal insulin has been shown to lower the entire 24-h blood glucose profile, and in combination with metformin the increase in weight after initiation of insulin treatment has been significantly reduced [ 9 ,10].”
BackgroundInsulin therapy in type 2 diabetes
Hollander, P. A. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200204000-00003 · Cited by 3
Parkner, T., Laursen, T., Chen, J., Møller, M. K., Thomsen, H. F., Jørgensen, C., Smedegaard, J., Lauritzen, T., & Christiansen, J. S. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100514 · Cited by 3
Intensive Insulin Therapy in Type 2 Diabetes
Edelman, S. V. (2007) · Insulin · doi:10.1016/s1557-0843(07)80069-8 · Cited by 3
Traitement médicamenteux du diabète de type 2 (deuxième partie)
Tielmans, A., Virally, M., Coupaye, M., Laloi-Michelin, M., Meas, T., & Guillausseau, P.-J. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2006.11.015 · Cited by 3
Therapeutic problems in type II diabetic patients developing insulin requirement
Leuténegger, M., Bertin, É., & Grulet, H. (1996) · Journal of Diabetes and its Complications · doi:10.1016/1056-8727(96)00043-8 · Cited by 3
Dixon, A. (2004) · Practical Diabetes · doi:10.1002/pdi.704 · Cited by 3
Improving Management of Type 2 Diabetes Mellitus: 3. Sulfonylureas
Samraj, G. P. N., Quillen, D. M., & Kuritzky, L. (1999) · Hospital Practice · doi:10.1080/21548331.1999.11443949 · Cited by 3
THE ECONOMIC IMPLICATIONS OF IMPLEMENTING EVIDENCE‐BASED DIABETIC TREATMENT STRATEGIES
Phillips, C. J. (1998) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1998.tb11600.x · Cited by 3
Modern pharmacotherapies for type 2 diabetes mellitus.
Hsia, S. H. (2001) · PubMed Central · Cited by 2
Kumari, D. (2023) · Journal of Pharmacology and Drug Delivery · doi:10.59462/jpdd.1.1.101 · Cited by 1
Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch-klinischer Bedeutung
Wehling, M., Burkhardt, H., Schwarz, S. T., Frölich, L., & Wedding, U. (2016) · Springer eBooks · doi:10.1007/978-3-662-48126-4_2 · Cited by 2
Is daytime insulin more physiologic and less atherogenic than bedtime insulin?
Kanat, M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.10.037 · Cited by 2
“The efficacy and safety of bedtime moderate or long acting insulin is evaluated with OAD such as sulfonylurea [13], metformin [15] and glitazon [16].”
BackgroundMethodBelhadj, M., Roula, D., Malek, R., Lezzar, A., Mimouni, S., & Zinaï, S. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70424-8 · Cited by 2
Insulinothérapie dans le diabète de type 2
Bosquet, F., & Hartemann, A. (2004) · EMC - Endocrinologie · doi:10.1016/j.emcend.2003.10.006 · Cited by 2
Tirado, R., & Caixàs, A. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)63005-0 · Cited by 2
Sewell, J., Costa, S. D., Dempsey, C., McHoy, A., Turner, E., Wamae, D., & Williams, J. (2006) · European Diabetes Nursing · doi:10.1002/edn.51 · Cited by 2
Antidiabetic Combination Therapy
Beck‐Nielsen, H., & Henriksen, J. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6_11 · Cited by 2
“However, for several reasons none of these studies turned out to be successful when compared with the combination of NPH insulin and SU or with treatment with regular insulin three times a day and NPH at night [19].”
ResultMANAGEMENT OF TYPE 2 DIABETES (NIDDM)
Mk, G., & Baliga, K. (2002) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(02)80014-4 · Cited by 2
A Simple Therapeutic Combination for Type 2 Diabetes
Yki‐Järvinen, H. (2000) · Hospital Practice · doi:10.1080/21548331.2000.11444032 · Cited by 2
Self-citationIs Weight Gain an Unavoidable Consequence of Insulin Therapy?
(2007) · The Internet Journal of Internal Medicine · doi:10.5580/1cb5 · Cited by 2
A Demographical Assessment of Different Insulin Regimens in Non-insulin Dependent Diabetics
Ali, S., Raza, S. A., Riaz, H., Butt, M., Saeed, H., Saleem, Z., Khan, T., & Ahmad, M. M. (2017) · Journal of Pharmaceutical Research International · doi:10.9734/bjpr/2017/33437 · Cited by 2
Place et modalités de lˈinsulinothérapie chez le diabétique de type 2
Bosquet, F., Hartemann–Heurtier, A., Chastang, N., & Jacqueminet, S. (2001) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(00)00327-1 · Cited by 2
Lindblad, C. I., Hanlon, J. T., Artz, M. B., Fillenbaum, G. G., & McCarthy, T. C. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51559.x · Cited by 2
“Since then, various new therapies have become available, as well as new data about the use of combination treatment for DM in the elderly.(6) In 1984, second-generation sulfonylurea oral agents (glyburide and glipizide) were introduced to the market, followed by metformin in 1995.”
BackgroundDiabetes Mellitus and Common Endocrine Conditions in the Elderly
Croxson, S. C. M. (2000) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860946486_0019 · Cited by 2
Type 2-diabetes og det metaboliske syndrom - diagnostik og behandling
Beck‐Nielsen, H., Henriksen, J. E., Hermansen, K., Madsen, L. D., Mandrup-Poulsen, T. R., Richelsen, B., & Schmitz, O. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2
Mazumdar, G., Swaika, B. C., & Dasgupta, A. (2012) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2012.21018 · Cited by 1
Monnier, L., & Colette, C. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70278-4 · Cited by 1
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1
Complicações agudas da diabetes Mellitus
de Família, M., Gallego, R., Caldeira, J., & de Diabetologia, C. D. S. (2007) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v23i5.10406 · Cited by 2
Son los nuevos análogos de insulina superiores a las viejas insulinas rápida y NPH
Garber, I. L. (2009) · Revista de Endocrinología y Nutrición · Cited by 1
Insulin therapy in patients with type 2 diabetes mellitus
Odeniyi, I. A., Olopade, O. B., & Fasanmade, O. A. (2019) · Journal of Clinical Sciences · doi:10.4103/jcls.jcls_5_18 · Cited by 1
“It is noteworthy that the rapid addition of insulin therapy is supported by a numerous studies showing improved treatment satisfaction and quality of life for Type 2 diabetic patients who had started using insulin.[19,20]”
BackgroundBurkhardt, H. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0912-0_10 · Cited by 1
Mojtahedzadeh, M., Lee, M. L., & Friedman, T. C. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.06.013 · Cited by 1
“The principle behind this regimen, originally called bedtime insulin/daytime sulfonylurea (BIDS) (Yki-Jarvinen et al., 1992), is that the bedtime insulin reduces the morning fasting plasma glucose (FPG), while the oral medications maintain glycemic control throughout the day.”
BackgroundGlycaemic management of type 2 diabetes
Davies, M. J., & Srinivasan, B. (2006) · Medicine · doi:10.1383/medc.2006.34.2.69 · Cited by 1
alenazi, A. S. S., Alenazi, A. A., Alonaze, N. A., alonazi, S. B., alonazi, W. B., alonazi, N. B., alanazi, A. H., alanizi, A. M., & Alharbi, Y. M. (2022) · doi:10.53555/jptcp.v29i04.4885 · Cited by 1
An Evidence-Based Approach to Type 2 Diabetes
Semple, R. K., & Dinneen, S. F. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-008-9_20 · Cited by 1
Moisey, R. S., Jenkins, R., & Nagi, D. K. (2007) · Practical Diabetes · doi:10.1002/pdi.1100 · Cited by 1
Is Avoiding Insulin Therapy an Achievable and Worthwhile Goal?
Ziel, F. H., & Nakahiro, R. K. (2000) · Endocrine Practice · doi:10.4158/ep.6.4.335 · Cited by 1
Common problems in outpatient management of patients with diabetes in the age of insulin analogues
DeWitt, D. E., & Dugdale, D. C. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00037-x · Cited by 1
“Many studies have shown that adding bedtime neutral protamine Hagedorn (NPH) insulin while continuing a daytime oral agent result in the best control with the least amount of weight gain and the lowest insulin dose, albeit at increased cost compared with insulin alone [7–11].”
BackgroundManagement of Type 2 Diabetes in the Geriatric Patient
Campbell, S. (2000) · Journal of Pharmacy Practice · doi:10.1177/089719000001300404 · Cited by 1
Insulin treatment in non-insulin dependent diabetes mellitus.
Misra, A. (1995) · PubMed · Cited by 1
Combination Therapy for Treatment of Type 2 Diabetes
McCall, A. L. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-16 · Cited by 1
Hensen, J. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-18 · Cited by 1
Consensus ADA/EASD 2009 : l’algorithme pour le traitement médical du diabète de type 2 est utile !
Sauvanet, J.-P. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70035-3 · Cited by 1
Weight Gain on Glucose-Lowering Agents
Lakhdar, A. F. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2834-2_32
Starting Insulin Treatment in Type 2 Diabetes
Vähätalo, M. (2015) · UTUPub (University of Turku)
Nogueira, K. C. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2012.tde-27072012-155318
Juurinen, L. (2014) · Työväentutkimus Vuosikirja
Brückel, J. (2001) · Springer eBooks · doi:10.1007/978-3-642-59539-4_11
Combined treatment of type 2 diabetes
Menéndez, E. (2009) · Anales del Sistema Sanitario de Navarra · doi:10.23938/assn.0798
Medikamentöse Therapie bei Insulinbehandlung
Berger, M., & Jörgens, V. (2001) · Springer eBooks · doi:10.1007/978-3-642-97548-6_20
Aspectos prácticos en el tratamiento del paciente diabético tipo 2
Chico, A. I., & Novials, A. (2004) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(04)76132-0
Strat??gies actuelles de prise en charge du diab??te de type 2
Charbonnel, B. H. (1998) · Disease Management & Health Outcomes · doi:10.2165/00115677-199804001-00002
“Différentes études[49-51] ont montré que cette association insuline intermédiaire au coucher/ sulfamides et/ou metformine dans la journée était efficace.”
BackgroundTargeting acute hyperglycaemia in clinical practice
Heller, S. R. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.10.008
La terapia combinada en la diabetes mellitus tipo 2
Goday, A. (2002) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(02)75610-7
Tratamiento de la diabetes tipo 2. Fármacos insulinosecretores
Pombo, J. L. H. (2000) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(00)70196-x
Combination oral agent and insulin therapy for type 2 diabetes mellitus
Passaro, M., & Ratner, R. E. (2001) · Current Diabetes Reports · doi:10.1007/s11892-001-0021-y
“Most studies favor BIDS therapy; it has been touted as being able to attain similar glycemic control with less weight gain [12, 14 ] and lower insulin doses [12,14‐16].”
MethodInsulin therapy in type 2 diabetes patients : balancing between evidence and experience
van Avendonk, M. J. P. (2010) · Utrecht University Repository (Utrecht University)
Insulin lispro for the treatment of type 2 diabetes
Fisher, M. (1999) · Hospital Medicine · doi:10.12968/hosp.1999.60.11.1233
McClain, D. A. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-375-0_11
Tip 2 Diyabette ‹nsülin Tedavisinin Etkinliini Belirleyen Faktörler
Muhtar, A., Uçak, S., Türkefl, G., & Altuntafl, Y. (2002)
Typ-2-Diabetes mellitus und genetische Defekte der β-Zell-Funktion
Dugi, K. A., Kassessinoff, T. A., & Nawroth, P. (1999) · Springer eBooks · doi:10.1007/978-3-642-58588-3_4
Terapêutica com insulina na diabetes tipo 2
Bacelar, C. (2005) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.32385/rpmgf.v21i6.10191
Mesquita, E. T., Junior, C. V. S., de Suplemento, Guimarães, J. I., Liberman, B., Mansur, A. J., Sousa, A. G. M. R., Sposito, A. C., Rassi, A., Lopes, A. A., et al. (2005)
Strategies for Non-Insulin-Dependent Diabetes Mellitus
Riddle, M. C. (1993) · Hospital Practice · doi:10.1080/21548331.1993.11442904
de Cardiologia, S. B., Simão, A. F. L., Cunha, V., Guimarães, C., Brandão, A. P., Brandão, A. A., Nogueira, A. D. R., Suplicy, H., & Guimarães, J. I. (2005)
Update of the evidence-based guideline of the German Diabetes Association
Matthaei, S., Bierwirth, R., Fritsche, A., Häring, U., Kellerer, M., Kunt, T., Schernthaner, G., Siegel, E. G., & Thienel, F. (2008)
Recetas prescritas: Un colaborador de la obesidad modificable
Cheskin, L. J., Bartlett, S. J., Zayas, R., Twilley, C. H., & Allison, D. B. (2001) · RET: revista de toxicomanías
Metadata
- Authors
- Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., Tulokas, T., Viikari, J., Karjalainen, J., & Taskinen, M.-R.
- Affiliations
- University of Turku (FI)
- Hatanpää Hospital (FI)
- Kuopio University Hospital (FI)
- Kymenlaakson keskussairaala (FI)
- Lapland Central Hospital (FI)
- University of Oulu (FI)
- University of Helsinki (FI)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-11-12
- Volume
- 327
- Issue
- 20
- Pages
- 1426-1433
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1964413807
- Cited by
- 324
- References
- 29
- Citations by year
- 2024: 1 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 7 · 2017: 9 · 2016: 5 · 2015: 7 · 2014: 5 · 2013: 12 · 2012: 8
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin regimens, NPH insulin, regular insulin, oral antidiabetic drugs, glycemic control, HbA1c, weight gain, subjective well-being, insulin therapy comparison, combination therapy, multiple daily insulin injections
- MeSH terms
- Administration, Oral, Adult, Aged, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Intravenous, Insulin, Lipoproteins, Male, Middle Aged, Monitoring, Physiologic, Patient Acceptance of Health Care, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
